Oliver Klein

Loading... 2 0 20 0 false
Credit Name
Oliver Klein
Full Name
Klein, Oliver
 
Department
 
Loading... 3 0 20 0 false

Publications

Refined By:
Subject:  immunotherapy

Results 1-5 of 5 (Search time: 0.002 seconds).

Publication YearTitleAuthor(s)
18-Apr-2022'Know thyself'- host factors influencing cancer response to immune checkpoint inhibitors.Gunjur, Ashray ; Manrique-Rincón, Andrea J; Klein, Oliver ; Behren, Andreas; Lawley, Trevor D; Welsh, Sarah J; Adams, David J
22022Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study.Dimitriou, F; Namikawa, K; Reijers, I L M; Buchbinder, E I; Soon, J A; Zaremba, A; Teterycz, P; Mooradian, M J; Armstrong, E; Nakamura, Y; Vitale, M G; Tran, L E; Bai, X; Allayous, C; Provent-Roy, S; Indini, A; Bhave, P; Farid, M; Kähler, K C; Mehmi, I; Atkinson, V; Klein, Oliver ; Stonesifer, C J; Zaman, F; Haydon, A; Carvajal, R D; Hamid, O; Dummer, R; Hauschild, A; Carlino, M S; Mandala, M; Robert, C; Lebbe, C; Guo, J; Johnson, D B; Ascierto, P A; Shoushtari, A N; Sullivan, R J; Cybulska-Stopa, B; Rutkowski, P; Zimmer, L; Sandhu, S ; Blank, C U; Lo, S N; Menzies, A M; Long, G V
3Nov-2021Combination immunotherapy with nivolumab and ipilimumab in patients with rare gynecological malignancies: results of the CA209-538 clinical trial.Klein, Oliver ; Kee, Damien ; Gao, Bo; Markman, Ben; da Gama Duarte, Jessica; Quigley, Luke; Jackett, Louise A ; Linklater, Richelle; Strickland, Andrew; Scott, Clare; Mileshkin, Linda; Palmer, Jodie ; Carlino, Matteo; Behren, Andreas; Cebon, Jonathan S 
49-Jun-2021PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma.Parakh, Sagun ; Musafer, Ashan; Paessler, Sabrina; Witkowski, Tom ; Suen, Connie S N Li Wai; Tutuka, Candani S A; Carlino, Matteo S; Menzies, Alexander M; Scolyer, Richard A; Cebon, Jonathan S ; Dobrovic, Alexander ; Long, Georgina V; Klein, Oliver ; Behren, Andreas
51-Feb-2017Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab.Menzies, A M; Johnson, D B; Ramanujam, S; Atkinson, V G; Wong, A N M; Park, J J; McQuade, J L; Shoushtari, A N; Tsai, K K; Eroglu, Z; Klein, Oliver ; Hassel, J C; Sosman, J A; Guminski, A; Sullivan, R J; Ribas, A; Carlino, M S; Davies, M A; Sandhu, S K; Long, G V